Skip to main content

Table 4 Association between cardiotoxicity risk and cumulative dose

From: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

Cumulative dose

Overall

Patients with

Patients without

p valuea

category, n (%)

(N = 509)

cardiac events

cardiac events

 
  

(n = 97)

(n = 412)

 

>0 and ≤35 mg/m2

82 (16.1)

6 (6.2)

76 (18.4)

REF

>35 and ≤75 mg/m2

204 (40.1)

19 (19.6)

185 (44.9)

>0.05

>75 and ≤105 mg/m2

149 (29.3)

33 (34.0)

116 (28.2)

<0.01

>105 mg/m2

74 (14.5)

39 (40.2)

35 (8.5)

<0.0001

  1. aFrom Poisson and logistic regression models; pairwise comparisons of cumulative dose categories are presented with lowest dose category as reference.
  2. REF=reference value.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us